Skip to content

289: Batch-to-Batch Variability Is a Design Failure, Not the Norm with Sandra Núñez - Part 1

September 22, 2026 · 19 min

Show notes

Batch-to-batch variability isn’t just a minor annoyance in bioprocess development; it’s often a systemic design flaw hiding in plain sight.

That’s the challenge Sandra Núñez, CEO of Amela Biosciences, set out to eliminate. Drawing on 15 years across Lonza, Medinova, Baxalta, and Biogen, she’s engineered a new generation of animal-free, recombinant protein matrices that promise researchers experimental consistency on demand.

Topics discussed:

  • The widespread issue of batch-to-batch variability and why Sandra argues it’s a design failure, not the norm (02:49)
  • The mechanics and biological tunability of Amela’s engineered protein matrices, and how this technology works (06:34)
  • How Amela’s recombinant protein bioinks differ from traditional animal-sourced extracts, enabling reproducibility (08:53)
  • Manufacturing insights: why the proteins are relatively straightforward to produce for research use (12:05)
  • Engaging with users to optimize and customize protein matrices for diverse tissue and assay applications (13:33)
  • The creation and use of protein libraries for specific user requirements and the flexibility this provides (16:20)
  • Definitions and roles of ‘bioinks’ in tissue modeling and 3D cell culture (16:52)

Smart insight: Reproducibility remains the cornerstone of reliable science. With innovative platforms like Amela Biosciences’ engineered protein matrices, the future of tissue engineering and in vitro biology looks not just reliable, but radically empowering. If you’re striving for consistency, customizability, and cutting-edge technology in your workflows, the era of animal-free, batch-consistent bioinks has arrived.

Here are four episodes that pick up the same threads: animal-free matrices, reproducibility by design, and building a biotech without a factory:

  • Episodes 271 - 272: From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture with Jan Hunik and Matt Baker
  • Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito
  • Episodes 275 - 276: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria Balet
  • Episodes 279 - 280: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher Locher

Connect with Sandra Núñez:
Website: www.amelabiosciences.com
Company LinkedIn: www.linkedin.com/company/amela-biosciences-ag
Sandra’s LinkedIn: www.linkedin.com/in/sandra-nunez-ch
Sandra’s email: [email protected]

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

All episodes of Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.